On Friday, Shares of Freeport-McMoRan Inc (NYSE:FCX), lost -1.90% to $9.80, as copper prices were lower following Federal Reserve Chairwoman Janet Yellen’s remarks Thursday and poor manufacturing data in China.
The dollar strengthened to a five-week high recently, after Yellen indicated in a speech on Thursday that she supports an interest rate hike by the year end, Reuters reported.
A stronger dollar is weighing on dollar-traded copper, as demand falls as the metal become relatively more expensive to foreign buyers.
Also weighing on copper prices are preliminary manufacturing data from China released Thursday that showed a seventh straight month of declines within China’s factory sector, adding to concerns about copper demand from the world’s largest metals consumer.
Freeport-McMoRan Inc. (FCX) is a natural resource company with an industry portfolio of mineral assets, oil and natural gas resources, and a production profile. FCX has organized its operations into six primary divisions: North America copper mines, South America mining, Indonesia mining, Africa mining, Molybdenum mines, and United States oil and gas operations.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD), declined -2.31% to $100.14, during its last trading session.
Gilead Sciences declared that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for the investigational, once-daily single tablet regimen Genvoya® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide (TAF) 10 mg) for the treatment of HIV-1 infection. The data presented in the MAA support the use of the regimen among adult and adolescent treatment-naïve individuals, virologically suppressed adults who switch regimens and adults with mild-to-moderate renal impairment.
The CHMP’s recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union. If authorized, Genvoya would be Gilead’s first single tablet regimen to contain TAF.
TAF is a novel investigational nucleotide reverse transcriptase inhibitor (NRTI) that has demonstrated high antiviral efficacy at a dose less than one-tenth that of Gilead’s Viread® (tenofovir disoproxil fumarate, TDF), in addition to improvement in surrogate laboratory markers of renal and bone safety as contrast to TDF in clinical trials in combination with other antiretroviral agents.
Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Company’s primary areas of focus comprise human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions.
Shares of Mondelez International Inc (NASDAQ:MDLZ), inclined 1.59% to $42.80, during its last trading session.
The Mondelēz International Foundation launched three well-being programs aimed at bringing nutrition education, active play and fresh foods to children and their families in Mexico, South Africa and the United States. This is part of the company’s multi-year, $50 million commitment to promote healthy lifestyles and address obesity. These new programs bring global community partners together in an effort to create school environments that encourage children and families to adopt lifelong healthy habits.
According to a 2014 Lancet report, the United States and Mexico have the highest rates of obesity in the world; South Africa is not far behind with the highest rates of obesity and overweight in sub-Saharan Africa.
“The three new well-being programs build on our ongoing commitment to community well-being and the fight against obesity, particularly among children. They are perfectly aligned with United Nations’ Sustainable Development Aims in the areas of addressing malnutrition and promoting good health and well-being,” said Nicole Robinson, President of the Mondelēz International Foundation. “As many schools start a new term, we’ll be working alongside our community partners, teachers and parents to establish the foundation for a healthy school year by promoting nutrition basics, encouraging active lifestyles and expanding access to nutritious foods.”
Mondelez International, Inc. is a snack food and beverage company. The Company manufactures and markets snack food and beverage products for consumers in about 165 countries around the world. The Company offers its brands in five product categories: biscuits (counting cookies, crackers and salted snacks); chocolate; gum and candy; beverages (counting coffee and powdered beverages), and cheese and grocery.
Finally, Cypress Semiconductor Corporation (NASDAQ:CY), ended its last trade with -0.11% loss, and closed at $8.76.
Cypress Semiconductor Corporation declared the debut of a regular blog by its president and chief executive officer, T.J. Rodgers. Once or twice a month, Rodgers will post on business, technology and administration topics. Current posts and a blog repository will be available in the “From the CEO” section of Cypress.com, under the “About Us” navigation tab on the Cypress home page (http://www.cypress.com). The blogs will also be available via the company’s Core & Code quarterly online magazine and technical blog at core.cypress.com and directly via core.cypress.com/ceoblog.
Rodgers’s first blog, available online now, addresses recent Cypress design win success, counting two “cross-selling” wins by the Cypress sales team in the wake of the company’s recent merger with Spansion. One of these was a platform win with a Tier 1 U.S. automaker, which selected Traveo™ automotive MCUs, HyperRAM™ and HyperFlash™ memories and analog power administration ICs (PMICs) developed by Spansion, and PSoC® programmable system-on-chip solutions developed by Cypress, for the infotainment cluster of its next-generation models.
Cypress Semiconductor Corporation is a provider of mixed-signal programmable solutions. The Company’s offerings comprise PSoC 1, PSoC 3, PSoC 4 and PSoC 5LP programmable system-on-chip families. It caters to markets, counting industrial, mobile handsets, consumer, computation, data communications, automotive and military.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
